The HYDRASHIFT daratumumab in vitro (IVD) diagnostic test resulting of a collaboration between Sebia and Janssen to provide the clinical community with better tools to monitor patients with multiple myeloma in line with the International Myeloma Group’s (IMWG) latest recommendations.
This assay, intended to be used with HYDRAGEL IF, mitigates the daratumumab mediated interference seen in immunofixation results for patients treated with DARZALEX®, a fully human monoclonal antibody that binds to CD38.
The benefit of HYDRASHIFT has been highlighted in several scientific publications, such as the Journal of Applied Laboratory Medicine (JALM) by AACC by Thoren, Ola Landgren et al., which shows:
Large menu with high quality results on gel electrophoresis.
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.